$AIM +164% 🚀 🔹 Massive move as AIM ImmunoTech hits a major Phase 2 DURIPANC milestone ahead of schedule 📈 🔹 Final subject enrollment completed for Ampligen

$AIM +164% 🚀 🔹 Massive move as AIM ImmunoTech hits a major Phase 2 DURIPANC milestone ahead of schedule 📈 🔹 Final subject enrollment completed for Ampligen + Imfinzi in metastatic pancreatic cancer 🔬 🔹 Primary endpoint evaluation expected Dec. 2026 — key catalyst now on watch 👀 🔹 Ebola oppor…